Project Grant R01HL184492
Award Date 9/1/26
Completion Date 6/30/30
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Scripps Research Institute $863,954 in funding on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance basic and translational research on the protein C pathway and its mechanisms in vascular, thrombotic, and inflammatory diseases. The award funds research into activated protein C (APC), a naturally occurring anticoagulant, with focus on understanding protein-protein interactions between APC and its...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $567,166 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop tunable multi-thrombolytic nanoformulations for treating ischemic stroke with minimal hemorrhagic risk. The research addresses limitations of current thrombolytic therapy—tissue plasminogen activator (tPA) carries serious intracranial hemorrhage complications, while plasmin, a more effective...
- The National Institutes of Health Office of the Director awarded $499,882 to SNJ Pharma Inc. on September 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to develop and evaluate a novel plasmin-independent thrombolytic agent for pulmonary embolism treatment. SNJ Pharma is conducting preclinical research to establish dose-response relationships and determine effective dosing of recombinant HTRA1 (rhtra1), a fibrinolytic enzyme designed to dissolve intravascular clots while...
- The National Heart, Lung, and Blood Institute awarded Emory University $391,211 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 1, 2026, to investigate alloimmune responses and anti-drug antibody formation against coagulation factor therapeutics in hemophilia patients. The research addresses inhibitor development—the formation of neutralizing antibodies against Factor VIII and Factor IX replacement therapies—which complicates treatment in approximately 30 percent of...
- The National Heart, Lung, and Blood Institute awarded University of California, Los Angeles $118,125 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of collagen type VIII in atherosclerotic plaque vulnerability. The research examines how collagen VIII, particularly its COL8A1 component, influences atherosclerotic plaque stability through its effects on smooth muscle cell recruitment and endothelial-to-mesenchymal transition. Aim 1...
- The National Heart, Lung, and Blood Institute awarded New York University $872,787 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic discovery and validation research on chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease. The award funds development of proteomic signatures to predict major adverse limb events (MALE) and major adverse cardiovascular events (MACE) in CLTI patients, and to guide...
- The National Heart Lung and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded $743,131 to the University of Wisconsin - Madison on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory mechanisms of the vessel wall in deep vein thrombosis. The research addresses thrombospondin-1 (TSP1), a matricellular protein upregulated in endothelial cells during DVT. The project tests...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic Arizona $249,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the pathogenic mechanisms of platelet factor 4 (PF4)–reactive antibodies in antibody-mediated thrombotic disorders including heparin-induced thrombocytopenia, vaccine-induced immune thrombotic thrombocytopenia, and monoclonal gammopathy of thrombotic significance. The project, titled "Determinants of...
- The National Heart, Lung, and Blood Institute awarded The Medical College of Wisconsin, Inc., $812,747 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct epidemiological, genome-wide association, and Mendelian randomization studies on the role of tissue-type plasminogen activator (tPA) in reducing lipoprotein(a) [Lp(a)] assembly. The research addresses how tPA, a serine protease that initiates fibrinolysis by converting plasminogen to plasmin, may...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $593,663 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thrombolysis resistance in acute ischemic stroke with large vessel occlusion. The project addresses the failure of intravenous thrombolysis with tissue plasminogen activator (TPA) to achieve successful recanalization in most eligible patients. Mayo Clinic will conduct three integrated research activities: define metabolic...